Waters Corporation
WAT
Positions held
Your positionsWAT isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Waters Corporation operates in the diagnostics and research industry, which is experiencing significant growth driven by increasing demand for advanced analytical instruments.
- In Q2 2026, revenue increased by 30% compared to the prior quarter, reaching $1.6 billion.
- The company's operating margin improved to -2.2% in the latest quarter, indicating a positive trend in operational efficiency.
- The company faces intense competition in the diagnostics sector, which may pressure margins and market share.
- Waters reported a net income loss of $136 million in Q2 2026, highlighting ongoing profitability challenges.
- The trailing P/E ratio stands at 110.49, suggesting the stock may be overvalued compared to its earnings potential.
Fundamentals
| Market cap | $42.13B | Enterprise value | $47.10B | Trailing P/E | 108.64 | Forward P/E | 25.95 |
| PEG | 1.62 | Price / book | 2.77 | Beta | 1.15 | Dividend yield | 0.00% |
| Revenue growth | 113.4% | Earnings growth | — | Gross margin | 56.3% | Operating margin | 9.4% |
| Profit margin | 3.6% | ROE | 1.9% | ROA | 3.6% | Debt / equity | 0.36 |
| Current ratio | 1.86 | Free cash flow | -$142.07M | Analyst recommendation | buy | Mean target | $456.70 |
| 52w high | $454.54 | 52w low | $282.77 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.6B | $1.3B | $932M | $800M | $771M | — |
| Op margin | -2.2% | -3.7% | 29.0% | 24.0% | 24.8% | — |
| Net income | -$136M | -$72.0M | $225M | $149M | $147M | — |
| Gross margin | 44.6% | 46.4% | 61.1% | 59.0% | 58.4% | — |
| Gross profit | $734M | $588M | $569M | $472M | $450M | — |
| Operating income | -$37.0M | -$47.0M | $271M | $192M | $191M | — |
- Revenue +30% vs prior quarter ($1.6B vs $1.3B).
- Gross margin 44.6% (was 46.4% prior quarter).
- Operating margin expanded to -2.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.2B | $3.0B | $3.0B | $3.0B | — |
| Op margin | 25.4% | 28.3% | 27.7% | 29.7% | — |
| Net income | $643M | $638M | $642M | $708M | — |
| Gross margin | 59.3% | 59.4% | 59.6% | 58.0% | — |
| Gross profit | $1.9B | $1.8B | $1.8B | $1.7B | — |
| Operating income | $803M | $838M | $818M | $883M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Here's Why You Should Retain WAT Stock in Your Portfolio for Now
2026-10-08 · Baird Adjusts Price Target on Waters to $495 From $456
2026-10-07 · Evercore ISI Adjusts Waters Price Target to $480 From $410
2026-10-06 · Barclays Adjusts Waters Price Target to $500 From $460, Maintains Overweight Rating
2026-10-06 · CellCarta, Waters Corporation collaborate on companion diagnostics
2026-10-05 · CellCarta Establishes Strategic Partnership with Waters to Advance Companion Diagnostics Development
2026-10-01 · Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call
2026-10-01 · Guggenheim Adjusts Price Target on Waters to $490 From $440, Keeps Buy Rating
2026-09-30 · 1 Volatile Stock with Promising Prospects and 2 We Avoid
2026-09-27 · The Bull Case For Waters (WAT) Could Change Following New At-Home HPV And Cell Analysis Push
2026-09-26 · Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum
2026-09-24 · 1 Growth Stock with All-Star Potential and 2 We Find Risky
Price (daily)
Full chart · RSI · MACD · patterns